Juan Fernandez, MD
Internal Medicine · Miami, FLNPI 1992803308
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,104 of the $15,078 with a category attached, or 67.0%. 32 manufacturers reported payments, led by Johnson & Johnson at 39.6% of the total. Reporting peaked in 2019 at $8,677 and has fallen 90.8% since, to $797 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $43.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Boehringer Ingelheim$2K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$1K
- Lilly USA, LLC$902
- Novo Nordisk$608
- plus $3K from 26 others
Across 239 payments — averaging $7683.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$1M
- GSK$343K
- Janssen Research & Development, LLC$225K
- Incyte Corporation$165K
- E.r. Squibb & Sons, L.L.C.$34K
- Pfizer$29K
What the payments were for
- Speaking & faculty fees$4,18028%
- Travel & lodging$7635%
- Food & beverage$10,10467%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 31 | $5,975 |
| Boehringer Ingelheim | 65 | $1,660 |
| Sanofi-aventis U.S. LLC | 24 | $1,291 |
| AstraZeneca | 42 | $1,159 |
| Lilly USA, LLC | 41 | $902 |
| Novo Nordisk | 26 | $608 |
| Bayer | 14 | $413 |
| Amarin Pharma, Inc. | 5 | $389 |
| Pfizer | 18 | $382 |
| Redhill Biopharma Inc. | 14 | $348 |
| Merck | 14 | $266 |
| Aerie Pharmaceuticals, Inc. | 2 | $250 |
| GSK | 14 | $249 |
| Novartis | 5 | $208 |
| Amgen | 7 | $131 |
| Genentech USA, Inc. | 1 | $125 |
| Alcon | 1 | $122 |
| Chiesi USA, Inc. | 1 | $89 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Dompe US, Inc. | 2 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Corcept Therapeutics | 2 | $38 |
| AbbVie | 2 | $37 |
| Calliditas Therapeutics US Inc. | 1 | $35 |
| Gilead | 2 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $29 |
| Medicure Pharma Inc. | 1 | $26 |
| Abbott | 1 | $22 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,078 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $63,725 |
| RybelsusSemaglutide | 28 | $53,462 |
| FarxigaDapagliflozin Propanediol | 53 | $51,168 |
| EliquisApixaban | 48 | $46,115 |
| OzempicSemaglutide | 29 | $27,353 |
| TrulicityDulaglutide | 24 | $25,269 |
| JanuviaSitagliptin Phosphate | 20 | $21,546 |
| TradjentaLinagliptin | 24 | $20,741 |
| MounjaroTirzepatide | 14 | $20,438 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $14,819 |
| EntrestoSacubitril/Valsartan | 16 | $14,580 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,151 |
| Tadalafil | 30 | $8,482 |
| VascepaIcosapent Ethyl | 23 | $7,941 |
| XareltoRivaroxaban | 12 | $6,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,660 | $84,46693 claims |
| Novo NordiskRybelsus, Ozempic, Levemir | $608 | $82,05769 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,159 | $65,98775 claims |
| PfizerEliquis | $382 | $46,11548 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $902 | $45,70738 claims |
| MerckJanuvia | $266 | $21,54620 claims |
| NovartisEntresto | $208 | $14,58016 claims |
| GSKTrelegy Ellipta | $249 | $10,15114 claims |
| Johnson & JohnsonXarelto | $5,975 | $6,57912 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $62 | $5,84111 claims |
| AbbVieSynthroid | $37 | $2,57523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.